{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T07:35:48Z","timestamp":1780385748229,"version":"3.54.1"},"reference-count":30,"publisher":"Scientific Scholar","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,6]]},"abstract":"\n Background & objectives:<\/jats:title>\n Survival of patients with multiple myeloma (MM) has improved in the past two decades following use of novel agents and autologous stem cell transplantation. To determine predictors of long-term outcome, data of MM patients who underwent autologous stem cell transplantation (ASCT) at a tertiary care centre in north India were retrospectively analyzed.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n Between 1995 and 2016, 349 MM patients underwent ASCT. Patients' median age was 52 yr, ranging from 29 to 68 yr, 68.2 per cent were males. Thirty three per cent patients had international staging system (ISS) Stage III and 68.5 per cent had received novel agents-based induction. High-dose melphalan (200 mg\/m2<\/jats:sup>) was used for conditioning; patients with renal insufficiency (estimated glomerular filtration rate <40 ml\/min) received melphalan 140-150 mg\/m2<\/jats:sup>.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n Post-transplant, 317 of 349 (90.8%) patients responded; complete [complete response (CR)] \u2212213 (61%)], very good partial response (VGPR) \u221262 (17.8%) and PR in 42 (12%)]. Induction with novel agents, pre-transplant chemosensitive disease, transplant in first remission and serum albumin (\u22653.5 g\/dl) were predictors of significant response. At a median follow up of 73 months, median overall survival (OS) was 90 months [95% confidence interval (CI) 70.8-109.2], and progression-free survival (PFS) was 41 months (95% CI 33.0-49.0). On multivariate analysis, achievement of CR post-transplant, transplant in first remission, ISS Stages I and II (vs. III), absence of extramedullary disease and serum albumin \u22653.5 g\/dl were predictors of prolonged OS. For PFS, achievement of post-transplant CR and transplant in first remission were predictors of superior outcome.<\/jats:p>\n <\/jats:sec>\n \n Interpretation & conclusions:<\/jats:title>\n Treatment with novel agents, achievement of complete remission post-transplant, ISS Stages I and II, absence of extramedullary disease and transplant in first remission were predictors of long-term survival for patients with MM.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/ijmr.ijmr_1593_18","type":"journal-article","created":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T10:17:29Z","timestamp":1567505849000},"page":"730-739","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":31,"title":["High-dose chemotherapy followed by autologous stem cell transplant for multiple myeloma"],"prefix":"10.25259","volume":"149","author":[{"given":"Lalit","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dev","family":"Ramavath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babita","family":"Kataria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akash","family":"Tiwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Raj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh Kumar","family":"Chellapuram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali","family":"Mookerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjit Kumar","family":"Sahoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabhat S.","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritu","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Om dutt","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahitagni","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Thulkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","reference":[{"key":"R1-6-20241212","first-page":"210","article-title":"Recent advances in the management of multiple myeloma","volume":"23","author":"Kumar","year":"2010","journal-title":"Nat Med J India"},{"key":"R2-6-20241212","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1182\/blood-2017-05-693606","article-title":"How I treat the young patient with multiple myeloma","volume":"132","author":"Gandolfi","year":"2018","journal-title":"Blood"},{"key":"R3-6-20241212","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe fran\u00e7ais du my\u00e9lome","volume":"335","author":"Attal","year":"1996","journal-title":"N Engl J Med"},{"key":"R4-6-20241212","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N Engl J Med"},{"key":"R5-6-20241212","doi-asserted-by":"crossref","first-page":"9227","DOI":"10.1200\/JCO.2005.03.0551","article-title":"High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: Long-term results of a randomized control trial from the group myelome-autogreffe","volume":"23","author":"Fermand","year":"2005","journal-title":"J Clin Oncol"},{"key":"R6-6-20241212","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1182\/blood-2005-03-1301","article-title":"High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: Long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA","volume":"106","author":"Blad\u00e9","year":"2005","journal-title":"Blood"},{"key":"R7-6-20241212","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1200\/JCO.2005.04.5807","article-title":"Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: Final results of phase III US intergroup trial S9321","volume":"24","author":"Barlogie","year":"2006","journal-title":"J Clin Oncol"},{"key":"R8-6-20241212","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.bbmt.2006.09.010","article-title":"High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Koreth","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"R9-6-20241212","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"key":"R10-6-20241212","doi-asserted-by":"crossref","first-page":"8000","DOI":"10.1200\/JCO.2016.34.15_suppl.8000","article-title":"Upfront autologous stem cell transplantation (ASCT) versus novel agent-based therapy for multiple myeloma (MM): A randomized phase 3 study of the European Myeloma Network (EMN02\/HO95MM trial)","volume":"34","author":"Cavo","year":"2016","journal-title":"J Clin Oncol"},{"key":"R11-6-20241212","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S1470-2045(15)00389-7","article-title":"Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: A randomised, multicentre, phase 3 trial","volume":"16","author":"Gay","year":"2015","journal-title":"Lancet Oncol"},{"key":"R12-6-20241212","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous transplantation and maintenance therapy in multiplemyeloma","volume":"371","author":"Palumbo","year":"2014","journal-title":"N Engl J Med"},{"key":"R13-6-20241212","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.LBA-1.LBA-1","article-title":"Comparison of autologous hematopoietic cell transplant (autoHCT), bortezomib, lenalidomide (len) and dexamethasone (RVD) consolidation with len maintenance (ACM), tandem autohct with len Maintenance (TAM) and autohct with len maintenance (AM) for up-front treatment of patients with multiplemyeloma (MM): primary results from the randomized phase III trial of the Blood and Marrow Transplant Clinical TrialsNetwork (BMT CTN 0702 \u2013 StaMINA Trial)","volume":"128","author":"Stadtmauer","year":"2016","journal-title":"Blood"},{"key":"R14-6-20241212","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/jamaoncol.2017.4600","article-title":"Autologous transplantation for newly diagnosed multiple myeloma in the era of novel agent induction: A systematic review and meta-analysis","volume":"4","author":"Dhakal","year":"2018","journal-title":"JAMA Oncol"},{"key":"R15-6-20241212","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/cam4.1283","article-title":"Analysis of long-term survival in multiple myeloma after first-line autologous stem cell transplantation: Impact of clinical risk factors and sustained response","volume":"7","author":"Lehners","year":"2018","journal-title":"Cancer Med"},{"key":"R16-6-20241212","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/ejh.12890","article-title":"Long-term follow-up of patients with multiple myeloma treated with total body irradiation-melphalan conditioning","volume":"99","author":"Munker","year":"2017","journal-title":"Eur J Haematol"},{"key":"R17-6-20241212","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/ejh.12869","article-title":"Impact of induction treatment before autologous stem cell transplantation on long-term outcome in patients with newly diagnosed multiple myeloma","volume":"98","author":"Gassiot","year":"2017","journal-title":"Eur J Haematol"},{"key":"R18-6-20241212","doi-asserted-by":"crossref","first-page":"922","DOI":"10.3324\/haematol.2016.158345","article-title":"Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma","volume":"102","author":"Gonz\u00e1lez-Calle","year":"2017","journal-title":"Haematologica"},{"key":"R19-6-20241212","doi-asserted-by":"crossref","first-page":"5055","DOI":"10.1182\/blood-2012-11-469452","article-title":"Autologous\/reduced-intensity allogeneic stem cell transplantation vs. autologous transplantation in multiple myeloma: Long-term results of the EBMT-NMAM2000 study","volume":"121","author":"Gahrton","year":"2013","journal-title":"Blood"},{"key":"R20-6-20241212","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1182\/blood-2011-01-332320","article-title":"Long-term prognostic significance of response in multiple myeloma after stem cell transplantation","volume":"118","author":"Martinez-Lopez","year":"2011","journal-title":"Blood"},{"key":"R21-6-20241212","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1016\/j.bbmt.2018.08.007","article-title":"Use of non-cryopreserved peripheral blood stem cells is associated with adequate engraftment in patients with multiple myeloma undergoing an autologous transplant","volume":"24","author":"Kulkarni","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"R22-6-20241212","first-page":"192","article-title":"Autologous stem cell transplantation for multiple myeloma: Long-term results","volume":"29","author":"Kumar","year":"2016","journal-title":"Natl Med J India"},{"key":"R23-6-20241212","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1200\/JCO.2015.65.0044","article-title":"International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment","volume":"34","author":"Dimopoulos","year":"2016","journal-title":"J Clin Oncol"},{"key":"R24-6-20241212","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","article-title":"Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma subcommittee of the EBMT. European group for blood and marrow transplant","volume":"102","author":"Blad\u00e9","year":"1998","journal-title":"Br J Haematol"},{"key":"R26-6-20241212","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"R27-6-20241212","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/bjh.15242","article-title":"Induction therapy for multiple myeloma: More is not necessarily better!","volume":"182","author":"Kumar","year":"2018","journal-title":"Br J Haematol"},{"key":"R28-6-20241212","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41408-018-0065-8","article-title":"Defining cure in multiple myeloma: A comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies","volume":"8","author":"Ravi","year":"2018","journal-title":"Blood Cancer J"},{"key":"R29-6-20241212","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1200\/JCO.2016.69.2517","article-title":"Depth of response in multiple myeloma: A pooled analysis of three PETHEMA\/GEM clinical trials","volume":"35","author":"Lahuerta","year":"2017","journal-title":"J Clin Oncol"},{"key":"R30-6-20241212","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","article-title":"Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: A meta-analysis","volume":"3","author":"Munshi","year":"2017","journal-title":"JAMA Oncol"},{"key":"R31-6-20241212","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/s41409-018-0250-1","article-title":"Cryopreserved versus non-cryopreserved peripheral blood stem cells for autologous transplantation after high-dose melphalan in multiple myeloma: Comparative analysis","volume":"54","author":"Bittencourt","year":"2019","journal-title":"Bone Marrow Transplant"}],"container-title":["Indian Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/02223309-201949060-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T23:01:48Z","timestamp":1751497308000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijmr.org.in\/high-dose-chemotherapy-followed-by-autologous-stem-cell-transplant-for-multiple-myeloma-predictors-of-long-term-outcome\/"}},"subtitle":["Predictors of long-term outcome"],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.4103\/ijmr.ijmr_1593_18","relation":{},"ISSN":["0971-5916"],"issn-type":[{"value":"0971-5916","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]}}}